Saturday, June 13, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 223 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

223 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 223 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

223 programs

Clinical programs

Page 2 of 5

  1. BCX17725

    Lacuna Pharma Pty Ltd

    Netherton Syndrome

    phase 2 small molecule active

    1 trial

  2. BV-2020/09

    Lacuna Pharma Pty Ltd

    Recurrent wheezing

    phase 2 small molecule active

    1 trial

  3. BW-20805 Injection

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema

    phase 2 small molecule active

    1 trial

  4. Bexmarilimab

    Lacuna Pharma Pty Ltd

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  5. BreAK CRC 001

    Lacuna Pharma Pty Ltd

    Unresectable locally advanced or metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  6. CAN-201 NDG

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 other active

    1 trial

  7. CMP-001-009

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  8. CND261

    Lacuna Pharma Pty Ltd

    Active, treatment refractory, ANCA-IgG-positive associated vasculitis

    phase 2 small molecule active

    1 trial

  9. COR1167-201

    Lacuna Pharma Pty Ltd

    Worsening Heart Failure

    phase 2 small molecule active

    1 trial

  10. CPH-LET01

    Lacuna Pharma Pty Ltd

    Moderate and severe horizontal forehead lines.

    phase 2 small molecule active

    1 trial

  11. CRD-4730, CRD-4730 matching placebo

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  12. CRD-4730-201

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    phase 2 small molecule active

    1 trial

  13. CRD-750-201

    Lacuna Pharma Pty Ltd

    Heart failure (HF) with reduced ejection fraction (HFrEF)

    phase 2 small molecule active

    1 trial

  14. CRD-750-202

    Lacuna Pharma Pty Ltd

    chronic heart failure

    phase 2 small molecule active

    1 trial

  15. CRN04894-09

    Lacuna Pharma Pty Ltd

    CONGENITAL ADRENAL HYPERPLASIA

    phase 2 other active

    1 trial

  16. CRN09682-191

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults

    phase 2 other active

    1 trial

  17. CS008

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  18. CT-P1-002

    Lacuna Pharma Pty Ltd

    Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of septic origin or cardiogenic shock due to Acute decompensated Heart Failure

    phase 2 other active

    1 trial

  19. CX11202

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  20. Cizutamig

    Lacuna Pharma Pty Ltd

    Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    phase 2 small molecule active

    1 trial

  21. Crofelemer Placebo Powder for Oral Solution

    Lacuna Pharma Pty Ltd

    Microvillous Inclusion Disease (MVID)

    phase 2 small molecule active

    1 trial

  22. DB-OTO

    Lacuna Pharma Pty Ltd

    Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)

    phase 2 small molecule active

    1 trial

  23. DCC-3014-01-001

    Lacuna Pharma Pty Ltd

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  24. DCC-3084, DCC-3084

    Lacuna Pharma Pty Ltd

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

  25. DCC-3116-01-001

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  26. DCR-PHXC-204

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 2 other active

    1 trial

  27. DNS-6288, DNS-6288

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  28. DUO2022_01

    Lacuna Pharma Pty Ltd

    Surgical wound infection/dehiscence caused by S. aureus and/or P. aeruginosa colonization

    phase 2 small molecule active

    1 trial

  29. EP-005

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial

  30. EP-262-201

    Lacuna Pharma Pty Ltd

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  31. EP0042-101

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 2 small molecule active

    1 trial

  32. EP0062-101

    Lacuna Pharma Pty Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  33. EPI-7386, Xtandi - 40 mg soft capsules

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  34. ET-20-049

    Lacuna Pharma Pty Ltd

    Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.

    phase 2 small molecule active

    1 trial

  35. EYP001-210

    Lacuna Pharma Pty Ltd

    Impaired renal function and suspected MASH

    phase 2 small molecule active

    1 trial

  36. Emrusolmin

    Lacuna Pharma Pty Ltd

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  37. Evaluation of the safety and efficacy of Cont... for Parkinson's disease

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 other active

    1 trial

  38. FTP-CLIN-01

    Lacuna Pharma Pty Ltd

    glabellar lines.

    phase 2 small molecule active

    1 trial

  39. Fancalen

    Lacuna Pharma Pty Ltd

    Fanconi anemia (subtype A)

    phase 2 small molecule active

    1 trial

  40. GEN-100

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  41. GRA.05.SPR.0001

    Lacuna Pharma Pty Ltd

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  42. GS-248-203

    Lacuna Pharma Pty Ltd

    Endometriosis related pain

    phase 2 small molecule active

    1 trial

  43. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 2 small molecule active

    1 trial

  44. HDP-101

    Lacuna Pharma Pty Ltd

    Relapsed or refractory Multiple Myeloma (r/r MM)

    phase 2 small molecule active

    1 trial

  45. HarMono-T 5 microlitres/mL gas and solvent for dispersion for injection/infusion

    Lacuna Pharma Pty Ltd

    Ultrasound contrast agent, for diagnostic purposes (to assess indeterminate kidney lesions)

    phase 2 small molecule active

    1 trial

  46. ICP-CL-00609

    Lacuna Pharma Pty Ltd

    Prurigo Nodularis

    phase 2 small molecule active

    1 trial

  47. ID-078A205

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  48. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

223 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.